Organisation Of Pharmaceutical Producers Of India

Multinational drugmakers are seeking relaxation of norms that govern the launch of new medicines and clinical trials of drugs in India.

Doctor-Pharma Nexus Part II: What drives drug prescription in India?

If doctors are concerned about the quality of generic drugs and hesitate to prescribe them, how do they decide which medicines patients should take?

Hike in cash aid for patients with rare diseases raises hopes for entry of new ‘orphan drugs’ in India

The change has come through a modification in the National Policy for Rare Diseases, which was first notified in 2021

Want regulatory reforms to expedite launch of new drugs in India: OPPI director general

For India to sustain its leadership position, it has to go big on R&D. India needs extensive collaboration between industry and academia and also the development of an innovation infrastructure, says Ananthkrishnan

Exclusive I Indians spend Rs 35,820 crore a year on minor ailments, finds novel survey by pharma body

Citing the findings of the study, the Organisation of Pharmaceutical Producers of India has argued that coming up with a robust policy on over-the-counter drugs will empower people and pharmacists but experts slam the idea saying it can be counterproductive for a country like India.

MNC drug body OPPI names Sharad Tyagi as President

Tyagi is currently Managing Director, Boehringer Ingelheim India. He replaces A Vaidheesh of GSK.

Customs duty on drugs irrational; patients will suffer: Biocon

Kiran Mazumdar Shaw, CMD, Biocon, calls this to be an irrational commentary from the government‘s side, as it will only the end-user—the patient—who will have to pay the increased cost.

Pharma cos demand raise in public spending on healthcare

As public spending on healthcare in India is among the lowest in the world, the increased public spending and sustainable financing mechanisms may improve access to healthcare in the country, Organisation of Pharmaceutical Producers of India (OPPI) said in a paper titled 'Healthcare Financing'.

FDI cap in pharma to hurt global investor confidence: Body

Imposing restrictions on foreign direct investment (FDI) in the pharmaceutical space would hurt overseas investment flows into India and will send a wrong signal to global investors, reports the Economic Times quoting president of the Organisation of Pharmaceutical Producers of India (OPPI) Ranjit Shahani.

Pharma industry fragmented, see more consolidation: Expert

In an interview with CNBC-TV18’s Menaka Doshi, Ranjit Shahani, President, Organisation of Pharmaceutical Producers of India and Chairman, Novartis, discusses the outlook for the pharma sector both from the M&A point of view as well as the FDI cap point of view.